2-(2,6-二甲基哌啶-1-基)乙腈 | 825-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(2,6-二甲基哌啶-1-基)乙腈
• 英文名称: 2-(2,6-dimethylpiperidino)acetonitrile
• 英文别名: 2-(2,6-Dimethylpiperidin-1-yl)acetonitrile
• CAS: 825-28-5
• 化学式: C₉H₁₆N₂
• mdl: MFCD09906883
• 分子量: 152.239
• InChiKey: NLOSAIIVENGARV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2,6-二甲基哌啶-1-基)乙腈 在 镍 氢气 、 乙醇 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以to give diamine 280 (2.52 g, 78%) as a colourless oil which的产率得到cis-2-(2,6-dimethyl-1-piperidinyl)ethylamine
  参考文献：
  名称：

  Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments

  摘要：

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，涉及它们的制备，以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗，无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。

  公开号：

  US07989451B2
• 作为产物：
  描述：

  2,6-二甲基哌啶 、 溴乙腈 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-(2,6-二甲基哌啶-1-基)乙腈
  参考文献：
  名称：

  [EN] PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS
  [FR] PYRAZOLOTHIAZOLE CARBOXAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR

  摘要：

  本公开涉及式(I)的化合物及其药学上可接受的盐。还描述了包含式(I)化合物的制药组合物，以及它们的使用和制备方法。

  公开号：

  WO2022136509A1

文献信息

• CYANOFLUOROPYRROLIDINE DERIVATIVE
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：EP1627870A1

  公开（公告）日：2006-02-22

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R1 and R2 are as defined in the specification, X represents a single bond or a C1-3 alkylene group, and R3 represents a group represented by the formula: -N(R4)COR5, -N(R4)SO2R5, -NR4R6, -SO2R5, -SO2NR4R5, -OCONR4R5, -CH=CH-R7 or -C≡C-R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y3 group)].

  一个用于预防或治疗可以通过抑制二肽基肽酶IV（DPPIV）来改善的疾病或病症的氰基氟代吡咯烷化合物，其具有公式（I）或药用上可接受的盐或水合物： [其中 A代表氢原子或氟原子， R1和R2如说明书中定义， X代表单键或C1-3亚烷基，并且 R3代表由公式表示的基团：-N(R4)COR5，-N(R4)SO2R5，-NR4R6，-SO2R5，-SO2NR4R5，-OCONR4R5，-CH=CH-R7或-C≡C-R7，或代表从至少含有一个氧和/或硫原子，并可能进一步含有氮原子的杂芳基组中选择的一个杂芳基组，以及一个6-成员氮杂芳环或9至11-成员的稠环（其中杂芳基组可以与一个或多个来自代Y3基团的取代基取代）。]
• Cyanofluoropyrrolidine derviative
  申请人：Fukushima Hiroshi

  公开号：US20060293297A1

  公开（公告）日：2006-12-28

  A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions capable of being improved by inhibition of dipeptidyl peptidase IV (DPPIV), diabetes mellitus, immune diseases and the like: [wherein A represents a hydrogen atom or a fluorine atom, R 1 and R 2 are as defined in the specification, X represents a single bond or a C 13 alkylene group, and R 3 represents a group represented by the formula: —N(R 4 )COR 5 , —N(R 4 )SO 2 R 5 , —NR 4 R 6 , —SO 2 R 5 , —SO 2 NR 4 R 5 , —OCONR 4 R 5 , —CH═CH—R 7 or —C≡C—R 7 , or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring or a 9- to 11-membered condensed ring thereof (wherein the heteroaryl group may be substituted with one or more substituents selected from the substituent Y 3 group)].

  一种氰基氟吡咯烷化合物，化学式为(I)，或其药学上可接受的盐或水合物，能够作为一种抑制二肽基肽酶IV（DPPIV）并预防或治疗疾病或症状的药物，例如糖尿病，免疫性疾病等。其中A代表氢原子或氟原子，R1和R2如规范中所定义，X代表单键或C13烷基，R3代表由以下公式表示的基团：—N(R4)COR5，—N(R4)SO2R5，—NR4R6，—SO2R5，—SO2NR4R5，—OCONR4R5，—CH═CH—R7或—C≡C—R7，或表示从含有至少一个氧和/或硫原子的杂环芳基中选择的杂环芳基，该杂环芳基还可以包含一个氮原子以及一个6元氮含杂环芳基或9-11元的缩合环（其中杂环芳基可以用来代替一个或多个取代基Y3）。
• Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments
  申请人：Hay Michael Patrick

  公开号：US20090186886A1

  公开（公告）日：2009-07-23

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，它们的制备以及它们作为低氧选择性药物和放射增敏剂用于癌症治疗，可以单独使用或与放射线和/或其他抗癌药物联合使用。
• WO2006/104406
  申请人：——

  公开号：——

  公开（公告）日：——
• Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport
  作者：Michael P. Hay、Kevin O. Hicks、Frederik B. Pruijn、Karin Pchalek、Bronwyn G. Siim、William R. Wilson、William A. Denny

  DOI：10.1021/jm070670g

  日期：2007.12.13

  Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.